ing was not confirmed in larger series.3 Fetal duct closure and changes induced directly in the pulmonary vasculature by the drug are postulated in the genesis of pulmonary hypertension.3 Reversible constriction of the fetal duct during maternal indomethacin therapy is well described.4 It seems appropriate to recommend that the fetuses of mothers who are receiving this group of drugs should be assessed by serial echocardiography. This is particularly desirable when polyhydramnios is the clinical problem, as this may be associated with a number of congenital abnormalities which themselves are associated with an increased incidence of structural congenital heart disease in the fetus. Administration of a duct-constricting drug to a fetus with duct-dependent heart disease should ideally be avoided, but at the very least it should not be done in ignorance and its effects should be monitored carefully by ultrasound imaging and Doppler assessments.
Postnatal ductal closure
Delayed closure of the arterial duct in term infants, even those with severe respiratory problems, is uncommon and is probably a manifestation of structural congenital heart disease. In contrast, the situation which exists in the preterm is that a normal duct is deprived of normal stimuli or subject to Prophylactic drug administration Prophylactic administration of indomethacin within one or two days of birth does reduce the incidence of symptomatic patent ductus arteriosus (sPDA)8 but in one study a high relapse rate was described.9 Unfortunately, prediction of which infants are at risk from sPDA is not very sensitive and concerns about the safety of indomethacin mean that its prophylactic use cannot be advocated. Ethamsylate, a drug which inhibits production of many prostaglandins, has been shown to be associated with a reduced incidence of sPDA in a trial of its value in preventing periventricular haerporrhage in the pre-term newborn.'0 Amato and colleagues" subsequently showed in a small group of infants that parenteral ethamsylate given within four hours of birth and then every six hours for four days was associated with less sPDA (2/10) than in controls (8/10) . This is too small a series to be able to recommend general use of ethamsylate to prevent sPDA. 
Therapeutic drug administration

